Published January 1, 2026
| Version v1
Journal article
Open
The Survivorship Passport for childhood cancer survivors: improvements and experience within several European PanCare projects
Authors/Creators
Authors/Creators
- Muraca M.1
- Saraceno D.2
- Stabile G.2
- Berti A.2
- Ngidi T.R.2
- Chronaki C.3
- Cangioli G.3
- Gazzarata R.4
- Nicolas B.1
- Beccaria A.1
- Tallone R.1
- Oberti S.1
- Pelanconi L.1
- Bagnasco F.5
- Cavalca G.6
-
Gull J.B.7
- Tormo Alcañiz M.T.7
- Galan A.O.7
- Uyttebroeck A.8
- Brié T.9
- Meersch E.V.10
- Rascon J.11
- Kapitancuke M.11
- Trinkunas J.12
- Langer T.13
- Neumann A.14
- Ladenstein R.15
- Bardi E.16
- Beyer S.17
- Schreier G.17
- Gredinger G.18
- O'Brian K.19
- Filibert A.-L.20
- van Kalsbeek R.21
- van der Pal H.21
- Kremer L.21
- Grabow D.20
- Haupt R.1
- 1. DOPO Clinic, Division of Pediatric Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, Genoa, 16147, Italy
- 2. Cineca Interuniversity Consortium, Bologna, Italy
- 3. HL7 Europe, Brussels, Belgium
- 4. HL7 Europe, Brussels, Belgium; Healthropy Srl, Savona, Italy
- 5. Epidemiology and Biostatistics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
- 6. University of Bologna, Bologna, Italy; Clinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
- 7. Instituto de, Investigación Sanitaria La Fe – Hospital Universitario y Politécnico La Fe, Valencia, Spain
- 8. Department of Oncology, Paediatric Oncology, KU Leuven
- 9. IT Department, University Hospitals Leuven, Leuven, Belgium
- 10. Nexuzhealth, University Hospitals Leuven, Leuven, Belgium
- 11. Center for Pediatric Oncology and Hematology, Information and Technology Development Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- 12. Vilnius Gediminas Technical University, Vilnius, Lithuania
- 13. Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
- 14. Institute of Medical Biometry and Statistics, Section for Clinical Research-IT, University of Luebeck and University Hospital Schleswig-Holstein, Lübeck, Germany
- 15. Anna Children's Cancer Research Institute, Vienna, Austria; Anna Children's Hospital, Vienna, Austria; Department of Paediatrics, Medical University of Vienna, Vienna, Austria
- 16. Anna Children's Cancer Research Institute, Vienna, Austria; Anna Children's Hospital, Vienna, Austria; Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria
- 17. Center for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Vienna, Austria; Institute for Neural Engineering, Graz University of Technology, Graz, Austria
- 18. Gesundheit Österreich GmbH, Vienna, Austria
- 19. Pintail, Limited, Dublin, Ireland
- 20. Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, German Childhood Cancer Registry University Medical Centerof the Johannes Gutenberg University Mainz, Mainz, Germany
- 21. Princess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands
Description
Background/purpose: As the population of childhood cancer survivors (CCS) continues to grow, personalized long-term follow-up (LTFU) care has become essential for ensuring optimal quality of life. The Survivorship Passport (SurPass) was developed to support efficient delivery of high-quality LTFU care, with the provision of treatment summaries and personalized follow-up recommendations. Updates to SurPass, from version v1.1 to v2.0, were made possible through two complementary European-funded projects: PanCareFollowUp and PanCareSurPass. Methods: Within PanCareFollowUp, SurPass was updated with new variables and algorithms based on International Guideline Harmonization Group/PanCare guidelines (v1.2) and tested in one clinic. During PanCareSurPass, the platform was updated to v2.0, featuring certification as Medical Device (MD) and interoperability with Electronic Health Information Systems, and deployed across clinical sites in six European countries. Results: The current SurPass v2.0 includes 242 variables and 47 algorithms for generation of the Standardized Care Plan. It is certified as MD and supports both manual and semi-automatic data entry through the adoption of Health Level Seven International Fast Healthcare Interoperability Resources (HL7-FHIR). The preliminary experience with SurPass delivered to 207 CCS in Italy within the PanCareFollowUp is reported. Conclusion: Interoperability via HL7-FHIR and the MD certification of the SurPass allow its use in clinical practice, and a reduction in time needed to generate the document providing homogeneous and personalized LTFU care for European CCS. Cost of interoperability through HL7-FHIR is offset by savings due to time reduction for TS generation. Experience in one clinic document the satisfaction of survivors who shared the document with their family doctors. Implications for Cancer Survivors: The Survivorship Passport (SurPass) provides childhood cancer survivors with a standardized, personalized summary of their cancer treatment and individualized follow-up recommendations based on international guidelines. Its implementation across multiple European countries demonstrates the feasibility of delivering consistent survivorship information that can support long-term follow-up, facilitate communication between survivors and healthcare providers, and promote informed engagement in survivorship care. © The Author(s) 2026.